The anti-OX40 monoclonal antibody rocatinlimab produced clinically meaningful improvements in adults with moderate-to-severe atopic dermatitis.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/will-rocket-trials-put-atopic-dermatitis-new-trajectory-2025a1000ptk?src=rss
Author :
Publish date : 2025-09-26 12:58:00
Copyright for syndicated content belongs to the linked Source.
